Pexastimogene devacirepvec

Drug Profile

Pexastimogene devacirepvec

Alternative Names: JX-594; Pexa-Vec; TG-6006

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jennerex Biotherapeutics
  • Developer Green Cross; Jennerex; National Cancer Institute (France); National Cancer Institute (USA); SillaJen Biotherapeutics; Transgene; Yonsei University College of Medicine; Yonsei University Health System
  • Class Antineoplastics; Gene therapies; Granulocyte-macrophage colony-stimulating factors; Oncolytic viruses
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hepatocellular carcinoma
  • Phase II Breast cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours
  • Phase I/II Colorectal cancer; Malignant melanoma
  • Preclinical Gastric cancer; Pancreatic cancer
  • No development reported Ovarian cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Colorectal-cancer(Refractory metastatic disease, Second-line therapy or greater) in South Korea (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in Canada (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top